Clinical TrialJun 12, 2026, 07:11 AM
MBX Biosciences Announces Positive One-Year Data for Canvuparatide
AI Summary
MBX Biosciences announced positive one-year data from its Phase 2 clinical trials for canvuparatide, a potential once-weekly treatment for chronic hypoparathyroidism. The data demonstrate sustained benefits, including maintenance of calcium homeostasis, improved kidney function, and normalized bone turnover markers. The drug was well-tolerated, and the company remains on track to initiate its Phase 3 pivotal trial in Q3 2026.
Key Highlights
- MBX Biosciences announced one-year data from Phase 2 Avail™ and OLE clinical trials of canvuparatide for chronic hypoparathyroidism.
- 57% of evaluable patients achieved responder status at one year, compared to 63% at 12 weeks.
- Pharmacokinetic data support potential for once-weekly dosing with consistent drug exposure.
- Mean serum calcium levels maintained within the normal range through one year.
- Mean estimated glomerular filtration rate (eGFR) increased from baseline and remained improved through one year.
- Markers of bone turnover showed expected patterns associated with PTH replacement therapy.
- Canvuparatide was generally well tolerated with no new safety signals observed during the one-year OLE.
- Phase 3 pivotal trial remains on track to initiate in Q3 2026.
Price Impact
More from MBX